Biogen Spent $5.6 Billion on Apellis. Then It Gutted the Lab.

One program appears to have dodged the axe, at least for now. APL-3007, a small interfering RNA therapeutic being tested alongside Syfovre in geographic atrophy, is reportedly still enrolling patients. Its direct connection to the crown jewel probably saved it.

A Commercial Play Dressed Up as a Deal

So why spend $5.6 billion if you're going to gut the research engine? Because the cash register was always the attraction.

Apellis' complement franchise generated $689 million in combined net product revenue in 2025. Syfovre accounted for roughly $587 million of that, while Empaveli contributed about $102 million. And the trajectory looks promising: Biogen has guided for mid-to-high-teens percentage annual revenue growth for the franchise through at least 2028.

William Blair analysts estimated the acquisition could add approximately $1.54 billion in annual sales by 2030. For a company watching its multiple sclerosis revenues decline, that's not just attractive; it's existential.

Syfovre commands roughly 60% market share in geographic atrophy and saw injection volumes climb 17% year-over-year in 2025, even as reported revenue dipped slightly due to free-goods programs and gross-to-net adjustments (the gap between list price and what the company actually collects). Management expects those adjustments to normalize in 2026, which should let revenue growth catch up to underlying demand.

Empaveli, meanwhile, is smaller but growing fast. Its Q4 2025 revenue of about $35 million represented a roughly 50% jump from the same quarter a year earlier. With significant room to run in the PNH market, its growth trajectory remains promising.

The math is straightforward. Biogen needed revenue now, not promising molecules that might pay off in seven years.

The Nephrology Shortcut

There's a subtler strategic angle here that doesn't get enough attention. Biogen has its own kidney drug in development: felzartamab, a CD38-targeting antibody in Phase 3 trials for three different kidney diseases, with the first data readout anticipated in 2027.

The problem? Nephrology is brand-new territory for Biogen. The company has openly acknowledged it lacked the medical affairs and commercial infrastructure to launch a kidney drug. Building that from scratch by 2027 would have been a scramble.

Apellis solved that problem overnight. Its established nephrology sales team, medical affairs presence, and relationships with key opinion leaders give Biogen a ready-made commercial platform for felzartamab. Think of it like buying a food truck that comes with a built-in customer base and a prime parking spot.

Biogen explicitly stated that Apellis' nephrology infrastructure would "accelerate and strengthen" its commercial readiness for felzartamab. The irony is thick: Biogen is suspending Apellis' own kidney research trials while planning to use Apellis' kidney-focused sales team to launch a different kidney drug.

This Playbook Has a Long, Ugly History

Biogen isn't inventing a new strategy here. It's following a well-worn script that Big Pharma has been running for decades.

When Amgen acquired Immunex in 2002, it wanted Enbrel, the blockbuster anti-inflammatory drug. Former Immunex scientists later described how Amgen ended most of Immunex's cancer immunotherapy research after closing. That research area, dismissed as non-core at the time, eventually became the foundation of modern oncology: checkpoint inhibitors, CAR-T therapy, and more. Immunex was "years ahead of the game," as one account put it, but those efforts "stalled out once it was gobbled up by a bigger fish."

The pattern repeats like a bad sequel. After Pfizer absorbed Wyeth in 2009, R&D spending dropped significantly, falling to roughly $6.5 to $7 billion by 2012. Research sites were shuttered. When Merck acquired Schering-Plough that same year, eight research facilities closed and R&D staff was cut by about 20%. After Actavis acquired Allergan in 2015, the CEO pledged to cut approximately $400 million, or about 18%, from the combined companies' research budget.

A European Commission study of 3,193 pharmaceutical transactions between 2014 and 2018 found something sobering. Of the 240 deals involving overlapping R&D pipelines, 89 (that's 37%) led to the discontinuation of overlapping projects with no obvious technical, safety, or clinical justification. Researchers flagged these as potential "killer acquisitions," where the acquirer buys innovation primarily to shelve it.

Biogen's situation isn't quite that cynical; it's not eliminating a competitor's pipeline to protect its own products. But the broader dynamic is the same. Early-stage science gets sacrificed on the altar of near-term commercial logic.

What the Complement Franchise Actually Is (and Why It Matters)

For readers who haven't been tracking complement biology, here's the quick version. Your immune system has a set of proteins called the complement system that helps identify and destroy pathogens. Think of it as your body's alarm-and-response network. When it misfires, it can damage healthy tissue, leading to conditions ranging from vision loss to kidney disease to blood disorders.

Both Syfovre and Empaveli work by inhibiting C3, a protein at the very center of the complement cascade. That's like cutting the power to the alarm system's main switchboard rather than trying to silence individual alarms downstream. Older complement drugs (like Alexion's Soliris and Ultomiris) target C5, a protein further down the chain. C3 inhibition is broader, which is both its promise and its complexity.

Biogen's acquisition validates C3-targeted complement medicine as a serious commercial platform, not just an academic curiosity. The question is whether gutting the research side limits where that platform can go next.

The Big Picture: Revenue Bridge or Innovation Dead End?

Biogen's leadership would argue this is disciplined portfolio management. You buy what's working, cut what's speculative, and focus your resources. The complement franchise fills a critical revenue gap as legacy MS products decline, and it gives the company time for newer bets like felzartamab to mature. Analysts aren't exactly shocked; the Street reads this as capital allocation discipline, not strategic confusion.

But zoom out, and a familiar tension emerges. Every time a large pharma company buys a biotech and strips it for parts, it sends a signal to the broader ecosystem. Early-stage researchers at acquisition targets know their work might have an expiration date measured in weeks, not years. Venture investors pricing early-stage complement biology programs have to wonder whether their exit will come with a demolition notice attached.

Apellis had been exploring complement biology across multiple disease areas: kidneys, blood, eyes, and more. Some of those programs might have failed on their own merits. Many early-stage programs do. But we'll never know, because they never got the chance to find out.

Biogen got its revenue engine. It got its nephrology sales team. It got two drugs generating nearly $700 million a year with strong growth ahead. By any near-term financial measure, the deal makes sense.

The cost is harder to measure. It's the research questions that won't get answered, the clinical trials that won't run, and the patients in diseases like kidney scarring who just lost a potential treatment option. That math doesn't show up on a quarterly earnings call. But it compounds over time, quietly, in the background, while the complement franchise hums along and the stock price does whatever it does.

Sometimes the most expensive thing a company buys is the science it throws away.

Big Pharma Is on a $123 Billion Shopping Spree (and It's Only June)

Pharma and biotech M&A has already topped $100 billion by mid-2026, with analysts projecting the biggest dealmaking year since 2019. Behind the frenzy: a massive patent cliff and two therapeutic areas every company wants to own.